BEIJING, May 15, 2025 /PRNewswire/ — Tsingke Biotech proudly participated in the AACR Annual Meeting 2025, held this April in Chicago, USA. As one of the world’s premier events in oncology research, AACR gathered global leaders from academia and industry to explore the future of cancer diagnostics and therapeutics.
At Booth #3255, Tsingke presented its comprehensive synthesis and expression service portfolio, offering essential support from early-stage discovery to preclinical development. Our platform drew attention for its capabilities in gene synthesis, oligonucleotide production, mRNA technologies, and protein expression.
What Tsingke Offers for Oncology Research
High-Throughput Nucleic Acid SynthesisCustom DNA/RNA oligos, siRNA, ASOComplex modifications: LNA, phosphorothioate, dual-labeled probesqPCR and NGS-grade primer/probe production mRNA Synthesis & Raw Materials SupplyIVT template synthesis with 5’/3′ modifications and Poly(A) tailsHigh-purity enzymes, capping reagents, modified nucleotides, and buffersReady to support LNP formulation workflows Protein Expression & Antibody ToolsGene synthesis, vector construction, and expression validationFast-turnaround expression services in HEK293/CHO systems Custom R&D Support for Novel TherapiessgRNA libraries, gene editing tools, and RNAi constructs
Building a Global Synthesis Engine for Cancer Innovation
Tsingke is committed to enabling biotech companies, CDMOs, and academic researchers with a one-stop synthesis platform—from molecular design and synthesis to expression and functional validation. By supporting critical steps in target discovery, validation, and preclinical development, we help accelerate the path from lab to clinic.
Interested in learning more or discussing a custom solution?Reach out to us at market@tsingke.com.cn or visit www.tsingke.com
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
